Catalyst Dossier · compiled by CeliA 🧫

PALVELLA THERAPEUTICS, INC. (PVLA)

Pharmaceutical Preparations · market cap $1.6B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Palvella Therapeutics (PVLA) is a small-pharma company with 14 employees and a ~$2.2B market cap built almost entirely on two Phase 3 assets: QTORIN 3.9% Rapamycin Anhydrous Gel for Microcystic Lymphatic Malformation (MLM) and PTX-022 for Pachyonychia Congenita (PC). The company carries $206M in cash (~57 months of runway) and no meaningful revenue in 2024-2025, making it a pure binary clinical-stage bet trading at a significant premium to its net asset value.

The catalyst path

2026-08-13Earningsimp 5/10

Pipeline

Asset	Phase	Indication
QTORIN 3.9% Rapamycin Anhydrous Gel	Phase 3	Microcystic Lymphatic Malformation
PTX-022	Phase 3	Pachyonychia Congenita

Price & technical context

3-month

+21.9%

6-month

+46.9%

12-month

+508.5%

52-wk range

$24.89–$154.84

vs 50-day MA

+21.4%

vs 200-day MA

+44.4%

Realized vol

91.0%

Max drawdown

-36.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PVLA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.